The global market for point-of-care cholesterol monitoring devices is set for significant growth, with projections indicating a rise from USD 440.6 million in 2022 to USD 514.7 million by 2028. This growth, reflecting a steady compound annual growth rate (CAGR) of 2.6%, comes in response to the growing need for efficient, convenient, and accurate cholesterol monitoring tools.
As cholesterol-related diseases continue to surge globally, there is an increasing demand for portable, user-friendly devices that allow for immediate and precise cholesterol readings. Point-of-care cholesterol monitoring devices are emerging as a crucial solution, enabling both patients and healthcare professionals to make timely, informed decisions that drive better health outcomes.
“With the increasing prevalence of cholesterol-related conditions worldwide, the importance of point-of-care cholesterol monitoring devices cannot be overstated,” said a representative from Future Market Insights (FMI), which conducted the survey. “Our projections indicate a promising future for these innovative tools, as they empower individuals to take proactive control of their cardiovascular health.”
The rising focus on preventive healthcare, along with significant advancements in diagnostic technology, is accelerating the adoption of these devices. Offering the convenience of at-home monitoring and the efficiency of clinical use, POC cholesterol devices reduce the need for frequent laboratory visits, making them an attractive option for individuals and healthcare settings alike.
These devices are playing an essential role in helping individuals stay on top of their cholesterol levels, enabling early interventions that can lead to better cardiovascular health management. As healthcare continues to evolve towards more accessible and proactive solutions, the global market for point-of-care cholesterol monitoring devices is expected to experience sustained growth.
Key Market Drivers:
- Rising prevalence of cardiovascular diseases worldwide
- Increasing demand for at-home healthcare solutions
- Advancements in portable diagnostic technologies
As the healthcare industry continues its shift towards patient-centered care, the importance of accessible, user-friendly monitoring solutions is expected to remain a crucial factor in the market’s growth trajectory. These devices represent a key component in preventive healthcare, enabling early detection and treatment of cholesterol-related conditions, ultimately improving patient outcomes.
Technological Advancements and Preventive Healthcare:
The integration of advanced technologies in healthcare, coupled with initiatives promoting preventive healthcare measures, is further bolstering the demand for point-of-care cholesterol monitoring devices. These devices empower healthcare professionals to perform on-the-spot testing, enhancing patient convenience and treatment efficacy.
Challenges and Market Constraints:
Despite the positive outlook, there are challenges impacting market growth. Concerns regarding accuracy and reliability, as well as regulatory hurdles, pose potential restraints. Point-of-care tests may not always match the accuracy of laboratory tests, and user errors can lead to result fluctuations. Additionally, stringent regulations for new device approval can cause delays and limit device variety, making healthcare providers and patients cautious in adopting these technologies.
Discover Market Trends: Access the Full Point-of-care Cholesterol Monitoring Device Market Report
Competitive Landscape:
The market for point-of-care cholesterol monitoring devices is dominated by a few major players, who frequently engage in strategic partnerships, product launches, and acquisitions to enhance their market presence. Recent developments include:
- In November 2019, ACON Laboratories, San Diego, CA, launched the On Call® Extra Mobile Glucose Monitoring Systems in Europe and Latin America.
- In April 2020, PTS Diagnostics partnered with MedPro Healthcare Sales Solutions, a leading healthcare contract sales organization.
Key Companies:
The market features several prominent companies, including:
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Abaxis, Inc. (a subsidiary of Zoetis Inc.)
- DiaSys Diagnostic Systems GmbH
- ACON Laboratories
- PTS Diagnostics
- Bioptik Technology, Inc.
- SD Biosensor, Inc.
- Jant Pharmacal Corporation, Inc.
- Nova Biomedical Corporation
- Beckman Coulter Inc. (a subsidiary of Danaher Corporation)
- SAMSUNG HEALTH CARE, Inc.
Market Segmentation:
The point-of-care cholesterol monitoring device market is segmented as follows:
- By Product: Instruments (Table-top Analyzers, Hand-held Analyzers), Testing Kits
- By Technology: Electrochemical Biosensor, Reflectance Photometry
- By Application: Dyslipidemia, Atherosclerosis, Hypercholesterolemia, Hypocholesterolemia, Others
- By End User: Hospitals, Diagnostics Centers & Laboratories, Ambulatory Surgical Centers, Home Care Settings
- By Region: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding China & Japan (APECJ), China, Japan, Middle East and Africa (MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
